Background {#Sec1}
==========

Mortality from sepsis is persistently high, and may even be rising despite decades of research \[[@CR1], [@CR2]\]. Promising pre-clinical immunomodulatory therapies have failed in clinical practice \[[@CR3]--[@CR5]\] perhaps attributable, in part, to differences between human and rodent immunology \[[@CR6]\]. However, an alternative explanation is that the heterogeneous etiology, presentation and progression of human sepsis generate confounding factors that distort the interpretation of clinical immunologic studies. Thus, the identification of appropriate controls, diagnostic accuracy, demographic influences and therapies with immunomodulatory off-target effects are critical considerations in interpreting translational work.

We therefore systematically reviewed the clinical experimental design of studies in three key areas of bed-to-benchside immunologic research in sepsis, focusing in particular on comparator groups and the documentation of known confounding factors. We also explored how the investigation of immune mechanisms in other clinical scenarios - trauma and major elective surgery - associated with the development of sepsis may help refine experimental design.

Methods {#Sec2}
=======

A Pubmed search was performed for the terms'Neutrophil respiratory burst' OR'Monocyte endotoxin tolerance' OR'Lymphocyte apoptosis' AND'Sepsis' OR'Trauma' OR'Surgery', restricted to adult human studies published between 03 January 1998 and 03 January 2013. The abstract of each paper was manually assessed for suitability. *In vitro* studies of healthy volunteer cells were excluded.

Clinical demographics {#Sec3}
---------------------

For all eligible manuscripts, we recorded the primary author, year of publication and clinical setting. The number, age, gender, clinical severity score of subjects and their corresponding controls, in whom the same assay of immune function was performed, were compared. The criteria used to define sepsis - complete with evidence for microbiological confirmation and independent adjudication of the sepsis diagnosis - were also recorded. Since immune cell effector function may change over the course of sepsis, we also recorded details of the timing of initial and subsequent blood samples, and the reason for blood sampling itself. Given that a recent report detected differences in genomic markers of inflammation that associate with survival within the first 24 h of intensive care admission \[[@CR7]\], we assessed whether samples were obtained within, or beyond, this 24-h window. Since several commonly used therapies used in intensive care medicine exhibit immune modulating effects, we also recorded whether common immunomodulatory agents including antibiotics \[[@CR8]\], glucocorticoids \[[@CR9]\] and sedative agents \[[@CR10]\] were documented. Reporting of pre-existing immunosuppressive or malignant disease - or their specific exclusion - was also recorded.

### Study aims {#Sec4}

The specific aims of each study were recorded with regard to the experimental context and primary conclusion. The context within which each of the three functional assays was studied was classified as: Pathophysiological - observational mechanistic studies detailing evolution of the assay response in clinical samples; Experimental - use of patient samples for more detailed experimental investigations beyond the assay itself; Clinical outcome - correlation of outcome measure with assay response; Biomarker comparison - correlation of alternative assay with functional assay.

Laboratory samples {#Sec5}
------------------

We recorded whether an *a priori* power analysis had been performed to determine the number of subjects/controls needed to refute the primary hypothesis. Sample timing and key aspects of experimental technique were compared between sepsis and control subjects. Associations made between immune cell function and clinical outcome were noted.

Statistics {#Sec6}
----------

Data are presented as mean ± SD, or median (interquartile range). Age data in primary studies was used to construct 95% confidence intervals in order to assess whether differences existed between control and study populations (NCSS 8, Kaysville, UT, USA).

Results {#Sec7}
=======

Fifty-seven eligible studies were identified, as summarised in Figure [1](#Fig1){ref-type="fig"}. Data is displayed into 3 tables for each immune assay, titled \"Principal features of studies\" (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}), \"Demographic information\" (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}) and \"Experimental conduct and exclusion criteria\" (Tables [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"} and [9](#Tab9){ref-type="table"}).Figure 1**Flow diagram illustrating study identification and inclusion** \[[@CR11]--[@CR66]\].

###### 

**Principal features of neutrophil respiratory burst studies**

  Author                       Study population                     Subjects ( ***n*** )   Control population             Control ( ***n*** )   Experimental context              Outcome measure correlated with immune readout
  ---------------------------- ------------------------------------ ---------------------- ------------------------------ --------------------- --------------------------------- ------------------------------------------------
  Santos \[[@CR12]\]           Sepsis                               49                     Healthy volunteer              19                    Clinical outcome                  Yes
  Paunel-Gorgulu \[[@CR19]\]   Trauma                               7                      Healthy volunteer              6                     Experimental                      No
  Bruns \[[@CR13]\]            Sepsis (cirrhotics)                  45                     Healthy volunteer and cohort   9 and 39              Pathophysiological                No
  Shih \[[@CR20]\]             Trauma                               32                     Healthy volunteer              Not provided          Biomarker comparison              Yes
  Kasten \[[@CR21]\]           Trauma                               3                      Healthy volunteer              3                     Pathophysiological                No
  Valente \[[@CR22]\]          Trauma                               24                     Healthy volunteer              11                    Pathophysiological                No
  Kawasaki \[[@CR26]\]         Elective surgery                     20 (10,10)             Cohort                         20                    Pathophysiological                No
  Frohlich \[[@CR27]\]         Elective surgery                     20                     Cohort                         20                    Experimental                      No
  Martins \[[@CR14]\]          Sepsis                               16                     Healthy volunteer              16                    Pathophysiological                Yes
  Barth \[[@CR15]\]            Sepsis                               27                     Healthy volunteer              11                    Biomarker comparison              No
  Mariano \[[@CR16]\]          Sepsis (renal replacement therapy)   7                      Haemodialysis patients         10                    Pathophysiological                No
  Quaid \[[@CR23]\]            Trauma                               7                      Healthy volunteer              Not provided          Pathophysiological                No
  Wiezer \[[@CR28]\]           Elective surgery                     22 (6,6,10)            Cohort                         22                    Pathophysiological/experimental   Yes
  Ahmed \[[@CR17]\]            Sepsis                               32                     Healthy volunteer              17                    Pathophysiological                No
  Shih \[[@CR29]\]             Trauma/surgery                       18                     Cohort and healthy volunteer   18                    Pathophysiological                No
  Ertel \[[@CR24]\]            Trauma                               10 (5,5)               Elective surgery               10                    Pathophysiological                No
  Ogura \[[@CR25]\]            Trauma                               24 (7 infected)        Cohort and healthy volunteer   24 and 15             Pathophysiological                Yes
  Pascual \[[@CR18]\]          Sepsis                               23                     Elective surgery               23                    Pathophysiological/experimental   No

*Subjects*: values within brackets refer to subgroups within the study.

###### 

**Principal features of monocyte tolerance studies**

  Author                     Study population             Subjects ( ***n*** )   Control population                             Controls ( ***n*** )   Experimental context   Outcome measure correlated with immune readout
  -------------------------- ---------------------------- ---------------------- ---------------------------------------------- ---------------------- ---------------------- ------------------------------------------------
  Liu \[[@CR30]\]            Sepsis                       2                      Healthy volunteer                              2                      Experimental           No
  Buttenschoen \[[@CR41]\]   Elective surgery             20                     Cohort                                         20                     Pathophysiological     No
  Pachot \[[@CR31]\]         Sepsis                       47                     Healthy volunteer                              21                     Pathophysiological     Yes
  West \[[@CR32]\]           Sepsis                       7                      Healthy volunteer, elective surgery and SIRS   16, 5 and 4            Pathophysiological     No
  Harter \[[@CR33]\]         Sepsis                       21                     Healthy volunteer                              12                     Pathophysiological     No
  Flohe \[[@CR40]\]          Surgery in trauma patients   16                     Healthy volunteer                              12                     Pathophysiological     No
  Escoll \[[@CR34]\]         Sepsis                       3 (5)                  Healthy volunteer                              3                      Pathophysiological     No
  Heagy \[[@CR39]\]          ICU patients (sepsis)        62                     Healthy volunteer                              15                     Clinical outcome       Yes
  Calvano \[[@CR35]\]        Sepsis                       18 (10)                Healthy volunteer                              15 (6)                 Pathophysiological     No
  Sfeir \[[@CR36]\]          Sepsis                       10                     Healthy volunteer                              10                     Pathophysiological     No
  Kawasaki \[[@CR42]\]       Elective surgery             20                     Cohort                                         20                     Pathophysiological     No
  Heagy \[[@CR37]\]          Sepsis                       58                     Healthy volunteer                              14                     Clinical outcome       Yes
  Bergmann \[[@CR38]\]       Sepsis                       30 (2)                 Healthy volunteer                              12                     Pathophysiological     No

*Subjects*/*controls*: numbers in brackets refer to subgroups within study.

###### 

**Principal features of lymphocyte apoptosis studies**

  Author                      Study population                             Subjects ( ***n*** )                    Control population                                                                                                              Controls ( ***n*** )                                 Experimental context                  Outcome measure correlated with immune readout
  --------------------------- -------------------------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------- ------------------------------------------------
  Roger \[[@CR43]\]           Sepsis                                       48                                      Healthy volunteer                                                                                                               15                                                   Pathophysiological                    No
  Bandyopadhyay \[[@CR58]\]   Trauma                                       113                                     Healthy volunteer                                                                                                               ?                                                    Pathophysiological                    No
  White \[[@CR11]\]           Sepsis                                       60                                      Gram negative infection and healthy volunteer                                                                                   15 and 20                                            Pathophysiological                    Yes
  White \[[@CR11]\]           Elective surgery (infective complications)   19                                      Cohort                                                                                                                          41                                                   "                                     "
  Zhang \[[@CR44]\]           Sepsis                                       19                                      Healthy volunteer                                                                                                               22                                                   Pathophysiological                    No
  Guignant \[[@CR45]\]        Sepsis                                       64                                      Healthy volunteer                                                                                                               49                                                   Pathophysiological                    No
  Vaki \[[@CR46]\]            Sepsis                                       48 (68)                                 Healthy volunteer                                                                                                               20                                                   Pathophysiological                    No
  Slotwinski \[[@CR62]\]      Elective surgery                             50 (26, 24)                             Cohort                                                                                                                          50                                                   Experimental/clinical outcome         No
  Gogos \[[@CR47]\]           Sepsis                                       PN 183, CAP 97, IA 100, PB 61, HAP 64   N/A                                                                                                                                                                                  Pathophysiological                    Yes
  Hoogerwerf \[[@CR48]\]      Sepsis                                       16                                      Healthy volunteer                                                                                                               24                                                   Pathophysiological                    No
  Yousef \[[@CR49]\]          Sepsis                                       32                                      SIRS and without SIRS                                                                                                           35/33                                                Patient outcome                       Yes
  Turrel-Davin \[[@CR50]\]    Sepsis                                       13                                      Healthy volunteer                                                                                                               15                                                   Biomarker comparison                  No
  Pelekanou \[[@CR51]\]       Sepsis                                       VAP 36                                  Other infections                                                                                                                32                                                   Pathophysiology                       No
  Papadima \[[@CR61]\]        Elective surgery                             40 (21, 19)                             Cohort                                                                                                                          40                                                   Pathophysiological                    No
  Delogu \[[@CR52]\]          Sepsis                                       16                                      ?'individuals'                                                                                                                                                                       Pathophysiological                    No
  Weber \[[@CR53]\]           Sepsis                                       16                                      Non-infected ICU and healthy volunteer                                                                                          10 and 11                                            Pathophysiological                    No
  Roth \[[@CR54]\]            Sepsis                                       15                                      Healthy volunteer                                                                                                               20                                                   Pathophysiological                    No
  Le Tulzo \[[@CR55]\]        Sepsis                                       47 (25, 23)                             SIRS and healthy volunteer                                                                                                      7 and 25                                             Pathophysiological/clinical outcome   Yes
  Hotchkiss \[[@CR56]\]       Sepsis                                       27 (FC 5) (3 intraop, 24 autopsy)       Critically ill non-septic and trauma                                                                                            16 and 25 (FC 6) (3 prospective, 13 retrospective)   Pathophysiological                    No
  Delogu \[[@CR63]\]          Elective surgery                             18                                      Cohort                                                                                                                          18                                                   Pathophysiological                    No
  Pellegrini \[[@CR59]\]      Trauma                                       17 (+13 burns)                          Healthy volunteer                                                                                                               17                                                   Clinical outcome/pathophysiological   (Correlate to MODS)
  Delogu \[[@CR64]\]          Surgical                                     15                                      Healthy volunteer                                                                                                               10                                                   Pathophysiological/patient outcome    Yes
  Hotchkiss \[[@CR60]\]       Trauma                                       10                                      Elective surgery                                                                                                                6 (all prospective)                                  Pathophysiological                    No
  Hotchkiss \[[@CR57]\]       Sepsis                                       20                                      Non septic prospective/non-septic retrospective/prospective trauma splenectomy/ prospective colectomy/retrospective colectomy   1/9/6/2/8                                            Pathophysiological                    No
  Sasajima \[[@CR65]\]        Elective surgery                             16 (11, 5)                              Cohort                                                                                                                          16                                                   Pathophysiological                    No
  Sugimoto \[[@CR66]\]        Elective surgery                             10 (5, 5)                               Cohort                                                                                                                          10                                                   Pathophysiological                    No

###### 

**Demographic information of neutrophil respiratory burst studies**

  Author                 Age                      Gender (%male)          Subject ethnicity detailed   Severity of subject disease   Subject drug exposure documentation                                                                                        
  ---------------------- ------------------------ ----------------------- ---------------------------- ----------------------------- ------------------------------------- ------------- --- ------------ --------------------------------- --- ------- ------- -------
  Santos \[[@CR12]\]     60 ± 17                  55.3 ± 18               N                            57                            53                                    N             N   APACHE II    17 (4 to 30)                      3   N       N       N
  Gorgulu \[[@CR19]\]    46 ± 4                   33 ± 2                  N\* (*p* \< 0.001)           74                            59                                    N             N   Mortality    9%                                1   N       N       N
  Bruns \[[@CR13]\]      58 (40 to 80)            45 (37 to 82); 58 (?)   0.437                        82                            73/48                                 0.341         N   \-                                             1   N       N       N
  Shih \[[@CR20]\]       33 ± 14                  ?                       N                            66                            ?                                     N             N   ISS          23                                2   N       N       N
  Kasten \[[@CR21]\]     36 ± 2                   38 ± 2                  *p* \> 0.05                  100                           100                                   *p* \> 0.05   N   ISS          23                                1   N       N       N
  Valente \[[@CR22]\]    75                       \>65                    N                            46                            ?                                     N             N   ISS          15.00                             1   N       N       N
  Kawasaki \[[@CR26]\]   52 ± 4; 54 ± 4           N/A                     N                            70                            70                                    *p* \> 0.05   N   ASA          I to II                           2   Y       N       N
  Frohlich \[[@CR27]\]   66 ± 10; 69 ± 6          N/A                     N                            40                            20                                    N             N   ASA          I                                 2   Y *t*   Y *t*   Y *t*
  Martins \[[@CR14]\]    50 ± 21                  31 ± 6                  N\* (*p* = 0.0011)           ?                             ?                                     N             N   Mortality    38%                               2   N       N       N
  Barth \[[@CR15]\]      N/S (36 to 82)           24 (22 to 50)           N                            60                            36                                    N             N   Mortality    37%                               1   N       N       N
  Mariano \[[@CR16]\]    67 ± 4                   ?                       N                            ?                             ?                                     N             N   \-                                             1   N       N       N
  Quaid \[[@CR23]\]      37 (20 to 71)            ?                       N                            ?                             ?                                     N             N   ISS          24 (17 to 34)                         N       N       N
  Wiezer \[[@CR28]\]     57 ± 3; 62 ± 2; 58 ± 5   ?                       N                            83, 66, 70                                                          N             N   APACHE III   Graphs (no difference)            3   N       N       N
  Ahmed \[[@CR17]\]      55 ± 6                   36 ± 16                 N\* (p \< 0.0001)            46                            ?                                     N             N   APACHE II    20 ± 1                            1   N       N       N
  Shih \[[@CR29]\]       42 ± 19                  N/S                     N                            55                            ?                                     N             N   ISS          26 ± 7.2                          3   N       N       N
  Ertel \[[@CR24]\]      N/S                      ?                       N                            ?                             ?                                     N             N   AIS          Head 4.5 ± 0.2, Chest 4.1 ± 0.1   1   N       N       N
  Ogura \[[@CR25]\]      40 ± 19                  35 ± 6                  N                            75                            ?                                     N             N   ISS          31 ± 10                           2   N       N       N
  Pascual \[[@CR18]\]    59 (27 to 81)            45 (27 to 81)           *p* \> 0.05                  51                            43                                    N             N   Mortality    21%                               1   N       N       Y *t*

*Age*: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N\*, not reported but we identified the significant *p* value from the original manuscript data. *Severity of subject disease*: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score \[[@CR87]\]; ASA, American Society of Anesthesiologists Physical Status Classification System \[[@CR85]\]; APACHE II: Acute Physiology and Chronic Health Evaluation II \[[@CR83]\], APACHE III, Acute Physiology and Chronic Health Evaluation III \[[@CR84]\]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A'*t*' signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.

###### 

**Demographic information of monocyte tolerance studies**

  Author                     Age              Gender (%male)   Subject ethnicity     Severity of subject disease   Subject drug exposure documentation                                                      
  -------------------------- ---------------- ---------------- --------------------- ----------------------------- ------------------------------------- --- --- ----------- --------------- ----- ---- --- ------
  Liu \[[@CR30]\]            ?                ?                N                     ?                             ?                                     N   N   ?           ?               1     N    N   N
  Buttenschoen \[[@CR41]\]   56 (33 to 88)    N/A              N                     70                            N/A                                   N   N   ?           ?               n/a   N    N   N
  Pachot \[[@CR31]\]         68 (54 to 76)    51 (42 to 65)    N                     62                            52                                    N   N   SAPS II     51 (±5)         2     N    N   N
  West \[[@CR32]\]           N/S              N/S              N                     42                            100; 20; 56                           N   N   ?           ?               2     N    N   N
  Harter \[[@CR33]\]         48 ± 20          \'Comparable'    N                     71                            12                                    N   N   APACHE II   13 ± 6          1     N"   N   N
  Flohe \[[@CR40]\]          47 ± 18          37 ± 14          N                     68                            50                                    N   N   ISS         39 ± 9          1     N    N   N
  Escoll \[[@CR34]\]         51 ± 12          49 ± 12          N                     ?                             ?                                     N   N   ?           ?               1     N    N   N
  Heagy \[[@CR39]\]          49 ± 3; 44 ± 8   ?                N                     ?                             ?                                     N   N   Mortality   20%, 9.6%       2     N    N   N
  Calvano \[[@CR35]\]        60; 61           58               N                     66; 66                        66                                    N   N   ?           ?               2     N    N   Y*t*
  Sfeir \[[@CR36]\]          63 ± 3           50 ± 7           N\* (*p* \< 0.0001)   80                            50                                    N   N   APACHE II   27 ± 5          1     N    N   N
  Kawasaki \[[@CR42]\]       ?                N/A              N                     ?                             N/A                                   N   N   ASA         I to II         1     N    N   N
  Heagy \[[@CR37]\]          49 ± 21          ?                N                     66                            ?                                     N   N   ?           ?               4     N    N   N
  Bergmann \[[@CR38]\]       60; 51           32               N                     ?                             ?                                     N   N   MODS        15 ± 1, 7 ± 1   2     N    N   N

*Age*: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N\*, not reported but we identified the significant *p* value from the original manuscript data. *Severity of subject disease*: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score \[[@CR87]\]; ASA, American Society of Anesthesiologists Physical Status Classification System \[[@CR85]\]; APACHE II: Acute Physiology and Chronic Health Evaluation II \[[@CR83]\], APACHE III, Acute Physiology and Chronic Health Evaluation III \[[@CR84]\]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A'*t*' signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.

###### 

**Demographic information of lymphocyte apoptosis studies**

  Author                      Age                                  Gender (%male)               Ethnicity             Severity of subject disease   Subject drug exposure documentation                                                                                                  
  --------------------------- ------------------------------------ ---------------------------- --------------------- ----------------------------- ------------------------------------- ------------- --- ----------- ---------------------------------------- ------- ------- ------- -------
  Roger \[[@CR43]\]           63 (37 to 82)                        55 (37 to 5)                 0.04                  50                            43                                    0.76          N   SAPS II     55 (12 to 92)                            2       N       Y *t*   Y *t*
  Bandyopadhyay \[[@CR58]\]   ?                                    \'Matched'                   N                     ?                             \'Matched'                            N             N   APACHE      \>21                                     1       N       N       N
  White \[[@CR11]\]           54 (72 to 80)                        Bacteraemia: 73 (70 to 82)   \>0.05                52                            Bacteraemia 40                        \>0.05        Y   APACHE      25 (21 to 28)                            2       N       N       N
  White \[[@CR11]\]           64 ± 2                               65 ± 1                       0.74                  68                            70                                    0.86          N                                                        2       N       N       N
  Zhang \[[@CR44]\]           58 ± 4                               59 ± 4                       N                     52                            50                                    N             N   APACHE II   26 ± 3                                   1       N       Y *t*   Y *t*
  Guignant \[[@CR45]\]        63 (54 to 73)                        ?                            N                     68                            N                                     N                 SAPS II     53(39 to 64)                             1       N       N       Y *t*
  Vaki \[[@CR46]\]            71 ± 2                               ?                            N                     54                            ?                                     N             N   APACHE II   20 ± 9                                   1 (3)   N       N       N
  Slotwinski \[[@CR62]\]      62 ± 9; 63 ± 9                       \-                           N                     5, 50                         \-                                    N             N   TNM         ?                                        1       N       Y *t*   N
  Gogos \[[@CR47]\]           67 ± 17; 68 ± 20; 54 ± 25; 64 ± 16                                *P* \< 0.0001         52, 62, 57, 67, 64                                                  *P* = 0.011   N   APACHE II   12 ± 7; 16 ± 9; 13 ± 8; 18 ± 8; 20 ± 5   3       N       N       N
  Hoogerwerf \[[@CR48]\]      57 ± 5,                              66 ± 5                       N\* (*p* \< 0.0001)   63                            50                                    N             N   APACHE II   19 ± 2                                   1       N       N       N
  Yousef \[[@CR49]\]          44 ± 9                               45 ± 9, 44 ± 10              N                     59                            60, 57                                N             N   SOFA        12 (7 to 14)                             3 (5)   N       N       N
  Turrel-Davin \[[@CR50]\]    60 ± 4                               \'Age matched'               N                     63                            \'Sex matched'                        N             N   SAPS II     51 ± 3                                   1       N       N       Y
  Pelekanou \[[@CR51]\]       69 ± 16                              64 ± 20                      0.099                 64                            43                                    0.300         N   APACHE II   18 ± 4; 15 ± 5                           1       N       N       Y
  Papadima \[[@CR61]\]        66 ± 7; 67 ± 10                                                   0.8                   85, 47                                                              0.54          N   ASA         I to II                                  1       Y *t*   Y *t*   Y *t*
  Delogu \[[@CR52]\]          ?                                    ?                            N                     ?                             ?                                     N             N   ?           ?                                        1       N       N       N
  Weber \[[@CR53]\]           56 ± 4                               61 ± 5,?                     \>0.05                68, 80                        ?                                     N             N   SAPS II     26 ± 2                                   1       N       N       Y
  Roth \[[@CR54]\]            56 ± 6                               52 ± 14                      N                     66                            \'Matched'                            N             N   APACHE      N/S                                      1       N       N       N
  Le Tulzo \[[@CR55]\]        55 ± 4; 64 ± 4                       72 ± 4; 55 ± 4               N\* (*p* \< 0.0001)   ?                             ?                                     N             N   SAPS II     33 ± 3; 58 ± 4                           2       N       N       N
  Hotchkiss \[[@CR56]\]       N/S                                  N/S                          N                     59                            56, ?                                 N             N   \-                                                   1       N       N       Y
  Delogu \[[@CR63]\]          47 ± 17                              \'Matched'                   N                     ?                             \'Matched'                            N             N   ASA         I to II                                  1       Y       N       Y *t*
  Pellegrini \[[@CR59]\]      44 (20--83)                          (18 to 60)                   N                     ?                             ?                                     N             N   ISS         25 (9 to 59)                             1       N       N       N
  Delogu \[[@CR64]\]          ?                                    \'Matched'                   N                     ?                             \'Matched'                            N             N   ASA         I to II                                  1       N       N       Y *t*
  Hotchkiss \[[@CR60]\]       18 to 46                             ?                            N                     90                            ?                                     N             N   ISS         N/S (9 to 50)                            1       N       N       N
  Hotchkiss \[[@CR57]\]       N/S                                  N/S                          N                     65                            ?                                     N             N   \-                                                   1       N       N       Y
  Sasajima \[[@CR65]\]        62 (55 to 74); 49(37 to 58)                                       N                                                   ?                                     N             N   ?           ?                                        1       N       N       N
  Sugimoto \[[@CR66]\]        N/S                                                               N                     50                                                                  N             N   ?           ?                                        1       N       N       Y *t*

*Age*: N/S, not summarised (tabulated data for every patient provided); question mark (?), not provided within the manuscript; N/A, not applicable. Statistical test result: N, not reported; N\*, not reported but we identified the significant *p* value from the original manuscript data. *Severity of subject disease*: The average clinical severity score of subjects with an index of spread listed in brackets. The number of severity groups which subjects were divided into is listed. ISS/AIS, Injury Severity Score/Abbreviated Injury Severity Score \[[@CR87]\]; ASA, American Society of Anesthesiologists Physical Status Classification System \[[@CR85]\]; APACHE II: Acute Physiology and Chronic Health Evaluation II \[[@CR83]\], APACHE III, Acute Physiology and Chronic Health Evaluation III \[[@CR84]\]. Subject drug use detailed: whether patient exposure to known immunomodulating drugs was documented. A'*t*' signifies that the timing of the drug administration in relation to blood sampling was clear from the study methodology.'Matched', paper provided no details but stated the control population was matched to the study population.

###### 

**Experimental conduct and exclusion criteria of neutrophil respiratory burst studies**

  Author                 Study population                     Sample timing                                                   Definition of sepsis   Microbiology results provided   Independent adjudication of sepsis diagnosis   Exclusion criteria immunosuppressive disease   Exclusion criteria malignancy   Primary conclusion of study (in relation to neutrophil respiratory burst)   
  ---------------------- ------------------------------------ --------------------------------------------------------------- ---------------------- ------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Santos \[[@CR12]\]     Sepsis                               72 h (Dx sepsis); 48 h (organ failure); onset of septic shock   2 (7 days)             1 A,B,C                         N                                              N                                              Y                               Y                                                                           Reactive oxygen species production by neutrophils is increased in sepsis, and \[it\] is associated with poor outcome
  Gorgulu \[[@CR19]\]    Trauma                               24 h (Hosp Adm)                                                 1                      2 A,B,C                         N                                              N                                              Y                               N                                                                           Fas stimulation of septic neutrophils promotes apoptosis and inhibits functionality, partially by non-apoptotic signalling
  Bruns \[[@CR13]\]      Sepsis (cirrhotics)                  24 h (Hosp Adm)                                                 1                      5                               Y                                              N                                              Y                               N                                                                           \[Within cirrhotic patients\] augmented neutrophil ROS release in response to *E. coli*...becomes exhausted in the presence of infection
  Shih \[[@CR20]\]       Trauma                               24 h (Hosp Adm)                                                 2 (3 days)             N                               N                                              N                                              Y                               Y                                                                           Plasma migration inhibitory factor is one of the important factors responsible for early neutrophil activation
  Kasten \[[@CR21]\]     Trauma                               48 to 72 h (Post-trauma)                                        1                      N                               N                                              N                                              Y                               N                                                                           Following trauma, there are concurrent and divergent immunological responses...hyper-inflammatory response by the innate arm...and hypo-inflammatory response by the adaptive arm
  Valente \[[@CR22]\]    Trauma                               48 h (Hosp Adm)                                                 3 (5 days)             N                               N                                              N                                              Y                               N                                                                           Injury results in differences in innate immune function in the elderly when compared with controls
  Kawasaki \[[@CR26]\]   Elective surgery                     Pre-insult                                                      5 (4 days)             N                               N                                              N                                              Y                               N                                                                           The innate immune system is suppressed from the early period of upper abdominal surgery
  Frohlich \[[@CR27]\]   Elective surgery                     Pre-insult                                                      2 (end of anaesth)     N                               n/a                                            n/a                                            Y                               Y                                                                           \[This study demonstrates\] suppression of neutrophil function by propofol *in vitro* \[but not\] *in vivo*
  Martins \[[@CR14]\]    Sepsis                               48 h (ICU Adm)                                                  1                      1 B,C                           Y                                              N                                              Y                               Y                                                                           Neutrophil function is enhanced in patients with sepsis
  Barth \[[@CR15]\]      Sepsis                               ?                                                               6 (5 days)             1C (\>4d)                       Y                                              N                                              N                               N                                                                           Endogenous G-CSF increases neutrophil function in patients with severe sepsis and septic shock
  Mariano \[[@CR16]\]    Sepsis (renal replacement therapy)   ?                                                               4 (1 day)              1, B,D                          N                                              N                                              N                               N                                                                           Sera from septic patients \[demonstrate\] an enhanced priming activity on neutrophils \[that is\] reduced by ultrafiltration
  Quaid \[[@CR23]\]      Trauma                               24 h (Hosp Adm)                                                 1                      N                               N                                              N                                              N                               N                                                                           \[After severe trauma\] IL-8 and GROα lose the ability to regulate the TNFα induced respiratory burst
  Wiezer \[[@CR28]\]     Elective surgery                     Pre-insult                                                      5 (7 days)             "clinical criteria"             N                                              N                                              Y                               N                                                                           Patients undergoing liver resection have an increased activation of leukocytes compared with other major abdominal surgery \[that is partially reversed\] by endotoxin neutralisation...with rBPI~21~
  Ahmed \[[@CR17]\]      Sepsis                               72 h (Proof of infection)                                       1                      1 A,B                           Y                                              Y                                              Y                               Y                                                                           Septic patients deliver fewer neutrophils to secondary inflammatory sites
  Shih \[[@CR29]\]       Trauma/Surgery                       24 h (Hosp adm)                                                 3+ (7 days)            1 A,B,C                         N                                              N                                              Y                               Y                                                                           Surgery after \[trauma\] has no effect on the priming of neutrophils
  Ertel \[[@CR24]\]      Trauma                               24 h (Hosp adm)                                                 2 (3 days)             N                               N                                              N                                              Y                               N                                                                           Severe trauma stimulates acute-phase priming in neutrophils
  Ogura \[[@CR25]\]      Trauma                               24 h (Post-trauma)                                              4 + 1 (21 days)        2 A B C                         Y                                              N                                              N                               N                                                                           Severe trauma stimulates acute-phase priming in neutrophils
  Pascual \[[@CR18]\]    Sepsis                               24 h (ICU adm)                                                  1                      1 A C                           Y                                              N                                              N                               N                                                                           Plasma of septic patients may have a profound effect on neutrophil response \[and\] differentiates between sepsis and non-sepsis samples

*Sample timing*: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each subject in total and over what time span? *Sepsis criteria*: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM 1992 Consensus Conference \[[@CR73]\]; 2, ACCP/SCCM Consensus Conference 2001 \[[@CR74]\]; 3, SSC Consensus Conference 2008 \[[@CR75]\]; 4, CDC NNIC \[[@CR86]\]; 5, Microbiology and clinical assessment; 6, Postmortem identification of infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. *Microbiology documentation*: Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of subsequent information?

###### 

**Experimental conduct and exclusion criteria of monocyte tolerance studies**

  Author                     Study population             Sample timing            Definition of sepsis   Microbiology results provided   Independent adjudication of sepsis diagnosis   Exclusion criteria immunosuppressive disease   Exclusion criteria malignancy   Primary conclusion of study (in relation to monocyte endotoxin tolerance)   
  -------------------------- ---------------------------- ------------------------ ---------------------- ------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------- --------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Liu \[[@CR30]\]            Sepsis                       ?                        1                      ? B C                           N                                              N                                              N                               N                                                                           TLR4 stimulation and human sepsis activate pathways that couple NAD^+^ and its sensor SIRT1 with epigenetic reprogramming
  Buttenschoen \[[@CR41]\]   Elective surgery             Pre-insult               4 (2 days)             N                               N                                              N                                              Y                               N                                                                           Cytokine liberation of mononuclear cells suggests a state of postoperative endotoxin tolerance
  Pachot \[[@CR31]\]         Sepsis                       72 h (onset sep shock)   2                      1C                              Y                                              Y                                              N                               N                                                                           CX3CR1 expression \[is\] severely down-regulated in \[septic\] monocytes and associated with lack of functionality
  West \[[@CR32]\]           Sepsis                       24 h (ICU adm)           1                      1 A, E                          Y                                              N                                              N                               N                                                                           Leukocytes of septic patients, but not SIRS, show LPS tolerance
  Harter \[[@CR33]\]         Sepsis                       ?                        1                      1 A B C                         Y                                              Y                                              N                               N                                                                           Endotoxin tolerance in septic patients does not depend solely on TLR-2 or TLR-4 expression
  Flohe \[[@CR40]\]          Surgery in trauma patients   48 h (ICU adm)           Mon, Thu.              1 A B C                         Y                                              N                                              Y                               Y                                                                           Initial trauma \[and\] major secondary surgery cause suppression of immune functions, whereas minor surgery does not
  Escoll \[[@CR34]\]         Sepsis                       48 h (onset sepsis)      1                      1 A                             Y                                              Y                                              Y                               Y                                                                           Monocytes from septic patients rapidly express IRAK-M mRNA when stimulated with LPS *ex vivo* \[unlike healthy volunteers\]
  Heagy \[[@CR39]\]          ICU patients (sepsis)        72 h (ICU adm)           1                      5                               N                                              Y                                              N                               N                                                                           ICU patients with...endotoxin tolerance have significantly poorer clinical outcomes
  Calvano \[[@CR35]\]        Sepsis                       ?                        1                      1 E A                           Y                                              N                                              N                               N                                                                           Cellular LPS hyporesponsiveness \[cannot\] be ascribed to significant alterations in...cell surface LPS binding proteins
  Sfeir \[[@CR36]\]          Sepsis                       24 (Sep Shock)           1                      1C                              Y                                              Y                                              Y                               N                                                                           Monocytes from patients with septic shock exhibit persistent IL-10 release at a time when TNF-α release is down-regulated
  Kawasaki \[[@CR42]\]       Elective surgery             Pre-insult               7 (7 days)             N                               N                                              N                                              Y                               N                                                                           LPS responsiveness...is altered from the early period of surgery
  Heagy \[[@CR37]\]          Sepsis                       72 h (ICU adm)           1                      5                               Y                                              Y                                              N                               N                                                                           Impaired TNF release may be a manifestation of monocyte endotoxin tolerance and may be useful to diagnose sepsis
  Bergmann \[[@CR38]\]       Sepsis                       ?                                               1 B C                           N                                              N                                              N                               N                                                                           The altered \[TNF-α release\] of septic blood to catecholamines might be due to altered reactivity of leukocytes

*Sample timing*: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each subject in total and over what time span? *Sepsis criteria*: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM 1992 Consensus Conference \[[@CR73]\]; 2, ACCP/SCCM Consensus Conference 2001 \[[@CR74]\]; 3, SSC Consensus Conference 2008 \[[@CR75]\]; 4, CDC NNIC \[[@CR86]\]; 5, Microbiology and clinical assessment; 6, Postmortem identification of infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. *Microbiology documentation*: Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of subsequent information?

###### 

**Experimental conduct and exclusion criteria of lymphocyte apoptosis studies**

  Author                      Study population                             Sample timing                Definition of sepsis             Microbiology results provided   Independent adjudication of sepsis diagnosis   Exclusion criteria immunosuppressive disease   Exclusion criteria malignancy   Primary conclusion of study (in relation to lymphocyte apoptosis)   
  --------------------------- -------------------------------------------- ---------------------------- -------------------------------- ------------------------------- ---------------------------------------------- ---------------------------------------------- ------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Roger \[[@CR43]\]           Sepsis                                       Before first abs             1                                3 B C                           Y                                              Y                                              Y                               Y                                                                   Concomitant T cell proliferation and T cell apoptosis are observed in human sepsis
  Bandyopadhyay \[[@CR58]\]   Trauma                                       ?                            Every 4 days (28 days)           N                               N                                              N                                              Y                               N                                                                   CD47 triggering, SHP-1 mediated NFkB suppression and elevated TRAIL levels increase...T cell apoptosis
  White \[[@CR11]\]           Sepsis                                       24 h (ICU adm/positive BC)   2 (7 days)                       1 B C                           N                                              Y                                              Y                               N                                                                   Patients with infection and sepsis have deficient IL-2 and IL-7 gene expression
  White \[[@CR11]\]           Elective surgery (infective complications)   Pre-insult                   3 (5 days)                       4                               N                                              Y                                              Y                               N                                                                   
  Zhang \[[@CR44]\]           Sepsis                                       24 h (sep shock)             1                                1C                              N                                              N                                              Y                               N                                                                   The expression of PD-1 on T cells \[is\] up regulated in septic shock
  Guignant \[[@CR45]\]        Sepsis                                       48 h (sep shock)             3 (10 days)                      1C                              Y                                              Y                                              N                               Y                                                                   PD-1 related molecules may constitute a novel immunoregulatory system involved in sepsis-induced immune alterations
  Vaki \[[@CR46]\]            Sepsis                                       12 h (organ failure)                                          2 B C                           Y                                              Y                                              Y                               N                                                                   These findings support...the existence of an early circulating factor in severe sepsis/shock, modulating apoptosis of CD4 lymphocytes
  Slotwinski \[[@CR62]\]      Elective surgery                             Pre-insult                   4 (7 days)                       N                               N                                              N                                              Y                               N                                                                   Preoperative enteral immunonutrition prevents postoperative decrease in lymphocyte subsets
  Gogos \[[@CR47]\]           Sepsis                                       24 h (signs of sepsis)       1                                2 B C                           Y                                              Y                                              Y                               N                                                                   Major differences of the early statuses of innate and adaptive immune systems exist between sepsis and severe sepsis/shock in relation the underlying type of infection
  Hoogerwerf \[[@CR48]\]      Sepsis                                       24 h (dx sepsis)             1                                2 A                             Y                                              Y                                              Y                               N                                                                   In patients with sepsis, alterations in apoptosis of circulating leukocytes occur in a cell-specific manner
  Yousef \[[@CR49]\]          Sepsis                                       ?                            1                                1 A B C                         N                                              N                                              Y                               N                                                                   Percentage of apoptotic lymphocyte median values \[could be\] an indicator of prognosis and survival in critically ill patients
  Turrel-Davin \[[@CR50]\]    Sepsis                                       48 h (sep shock)             2 (5 days)                       1C                              Y                                              Y                                              N                               N                                                                   Pro-apoptotic genes BID and FAS appear to constitute promising apoptosis markers
  Pelekanou \[[@CR51]\]       Sepsis                                       24 h (signs of sepsis)       1                                1 2 A B C                       Y                                              Y                                              Y                               N                                                                   Decrease of CD-4 lymphocytes...is characteristic of sepsis arising in ventilator associated pneumonia
  Papadima \[[@CR61]\]        Elective surgery                             Pre-insult                   2 (1 day)                        N                               \-                                                                                            Y                               Y                                                                   No alterations in lymphocyte counts \[and\] subpopulations \[following use of epidural anaesthesia\]
  Delogu \[[@CR52]\]          Sepsis                                       24 h (sep shock)             1                                ? C                             Y                                              N                                              N                               N                                                                   Blood caspase-1 elevated in sepsis. IL-6 correlates with apoptotic rate and caspase-9 expression in lymphocytes
  Weber \[[@CR53]\]           Sepsis                                       4 h (sev sepsis)             1                                1 B                             N                                              N                                              Y                               Y                                                                   In early severe sepsis...induction of...Bim,Bid,Bak and downregulation of Bcl-2 and Bcl-xl is observed
  Roth \[[@CR54]\]            Sepsis                                       ?                            1                                1 A B C                         N                                              N                                              N                               N                                                                   These findings strongly suggest that in septic patients Th1 T cells are selectively susceptible to apoptosis
  Le Tulzo \[[@CR55]\]        Sepsis                                       +ve microbiology ±3 days     2 (6 days)                       1 B C E                         Y                                              N                                              N                               N                                                                   Lymphocyte apoptosis is rapidly increased in...septic shock...and leads to a profound and persistent lymphopaenia associated with poor outcome
  Hotchkiss \[[@CR56]\]       Sepsis                                       6 h (death)                  1                                6                               Y                                              N                                              Y                               N                                                                   Capsase 9 mediates profound progressive loss of B and CD4 T helper cells in \[severe\] sepsis
  Delogu \[[@CR63]\]          Elective surgery                             Pre-insult                   3 (4 days)                       N                               N                                              N                                              Y                               Y                                                                   Surgical trauma is associated with a significant but transient increase in lymphocyte commitment to apoptosis
  Pellegrini \[[@CR59]\]      Trauma                                       ?                            2/week (until death/discharge)   N                               N                                              N                                              N                               N                                                                   Increased levels of apoptosis are not directly associated with negative trauma patient outcome
  Delogu \[[@CR64]\]          Surgical                                     Pre-insult                   3 (4 days)                       N                               N                                              N                                              Y                               Y                                                                   Surgical trauma upregulates lymphocyte death signalling factors and downregulates survival factors. Increased apoptosis of CD8+ cells maybe associated with greater risk of postsurgical infection
  Hotchkiss \[[@CR60]\]       Trauma                                       10 h (injury to surgery)     1                                N                               N                                              N                                              N                               N                                                                   Focal apoptosis of intestinal epithelial and lymphoid tissues occurs extremely rapidly after injury
  Hotchkiss \[[@CR57]\]       Sepsis                                       6 h (death)                  1                                6                               Y                                              Y                                              N                               N                                                                   Caspase-3 mediated apoptosis causes extensive lymphocyte apoptosis in sepsis
  Sasajima \[[@CR65]\]        Elective surgery                             Pre-insult                   5 (7 days)                       N                               N                                              N                                              N                               N                                                                   Transient T cell apoptosis occurs after major operations
  Sugimoto \[[@CR66]\]        Elective surgery                             Pre-insult                   4 (4 days)                       N                               N                                              N                                              N                               N                                                                   Enhanced FasL expression is likely to be related to systemic inflammatory responses induced during the perioperative period

*Sample timing*: Were control samples taken at the same time point after the inflammatory stimulus as subject samples? When was the first sample taken from the subject? How many samples were taken for each subject in total and over what time span? *Sepsis criteria*: The criteria used to enrol subjects into the study. Where subgroups of these criteria were used (e.g. septic shock) these are detailed. 0, not stated; 1, ACCP/SCCM 1992 Consensus Conference \[[@CR73]\]; 2, ACCP/SCCM Consensus Conference 2001 \[[@CR74]\]; 3, SSC Consensus Conference 2008 \[[@CR75]\]; 4, CDC NNIC \[[@CR86]\]; 5, Microbiology and clinical assessment; 6, Postmortem identification of infection; N, infection not considered; question mark (?), criteria not described. Sepsis severity groups enrolled: A = sepsis, B = severe sepsis, C = septic shock, D = acute renal failure, E = SIRS. *Microbiology documentation*: Were causative organisms clearly isolated and identified? Were additional steps taken to define whether the subject had sepsis beyond the initial clinical diagnosis, i.e. retrospective review of the case in light of subsequent information?

Source of experimental control subjects {#Sec8}
---------------------------------------

No studies reported *a priori* power analyses based on either preceding laboratory data or *ex vivo* clinical research. The majority of studies (42/57; 74%) used case--control methodology. Control samples were obtained from healthy volunteers in (35/42; 83%), with the remainder using a variety of loosely defined clinical phenotypes (Figure [2](#Fig2){ref-type="fig"}, Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). The exception was elective surgical patients, where preoperative samples served as appropriate controls. Cohort methodology, where samples including controls were obtained serially from the same patient, was employed in 14/57 (25%) of studies. The majority of cohort studies were conducted in elective surgical patients (12/14; 86%).Figure 2**Identification of experimental control groups.** The specific details for Hospital/ICU patients are detailed within Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Within cohort study pre-insult baseline samples were taken from the study population, allowing them to act as their own experimental control.

Age, gender and ethnicity {#Sec9}
-------------------------

Advanced age is associated with progressively impaired innate and adaptive immunity \[[@CR67]\]. Less than half of case control studies (20/42; 48%) reported the age distribution of both study and control populations. In studies where age was reported, the critically ill patients studied were often older than the control population. Female gender is associated with improved clinical outcomes following sepsis \[[@CR68], [@CR69]\] and increased longevity compared to males in general. Information on gender was provided in (26/42; 62%) of case--control studies. Significant variation in the incidence of sepsis has been reported according to ethnicity \[[@CR70]\], which may reflect residual confounding or plausible biologic differences in susceptibility. However, only one study reported the ethnicity of patients.

Co-morbidity {#Sec10}
------------

Various comorbidities ranging from cardiac failure to active malignancy are associated with important deleterious alteration in effective immune function, independent of those described in sepsis \[[@CR71], [@CR72]\]. The majority of studies (34/57; 60%) excluded patients with overt immunosuppression while a minority (8/57; 14%) excluded those with malignancy (Figure [3](#Fig3){ref-type="fig"}).Figure 3**Documentation of patients' comorbid disease.**

Clinical definition of sepsis {#Sec11}
-----------------------------

A high proportion of studies (26/33; 79%) defined sepsis in accordance with the ACCP/SCCM \[[@CR73], [@CR74]\] or Surviving Sepsis Campaign (2008 update) \[[@CR75]\] criteria. Of those studies which used standard consensus conference criteria, (15/26, 58%) included patients with'sepsis', (20/26; 77%) included those with'severe sepsis' and (24/26, 92%) included those with'septic shock'. In a large minority of these 26 studies (11/26; 42%), sub-categories defining sepsis were not compared separately, but combined. Immunologic studies in trauma and surgical patient samples usually did not document (18/24; 75%) whether patients developed an infection during the course of the study. In these studies, the majority (5/6) used established consensus conference criteria.

Microbiological definitions of sepsis {#Sec12}
-------------------------------------

Independent adjudication of the definition of sepsis used in studies was undertaken in 17/57 (30%) of studies. Since recent basic laboratory studies have demonstrated that the clinical signs/symptoms of sepsis are frequently mimicked by non-pathogenic molecules \[[@CR76], [@CR77]\], we sought to establish whether microbial evidence for sepsis was presented. Microbiological data were provided in 25/57 (44%).

Severity of critical illness {#Sec13}
----------------------------

A minority of studies (19/57; 33%) provided data on organ dysfunction related to sepsis severity, such as APACHE-II or SAPS II. When a severity index was used, a wide range was reported within individual studies suggesting substantial heterogeneity. In studies where mortality was reported (4/57; 7%), severity of critical illness was not reported in those patients who survived.

Timing of experimental samples {#Sec14}
------------------------------

The timing of the index blood sample obtained from septic patients was described in the majority (26/33; 79%) of cases. However, the criteria for initial sampling were not comparable between studies and was most frequently defined by the severity of sepsis (Figure [4](#Fig4){ref-type="fig"}). These triggers included hospital admission (1/26), ICU admission (5/26), proof of infection (2/26), diagnosis of sepsis (5/26), onset of sepsis (14/26; 54%), onset of organ failure (3/24) and onset of septic shock (7/26) - the remaining two samples were from autopsy studies. Multiple criteria for sampling were often used and dependent upon the severity of patient illness. Approximately half of all studies (14/26; 58%) obtained an initial sample within 24 h of hospital admission. Similar patterns of sample timing were described for trauma patients. Repeat samples were often undertaken, but over highly variable intervals that were frequently not defined *a priori*. By contrast, all 12 studies undertaken in the elective surgical setting obtained preoperative control samples, with subsequent samples taken on predefined postoperative days.Figure 4**Event trigger used for index blood sample to be taken within studies of septic patients.**

Therapies as potential confounders {#Sec15}
----------------------------------

Commonly administered therapies in intensive care impact directly on immune function \[[@CR8]--[@CR10]\]. We assessed reporting of three of the commonest therapies with established immunomodulatory properties and found that only up to a quarter of studies documented their use (Figure [5](#Fig5){ref-type="fig"}). Specifically, these were sedative agents (4/57; 7%), antibiotics (6/57; 11%) and steroids (15/57; 26%).Figure 5**Documentation of drug exposure of the study population.**

Experimental conduct and outcomes {#Sec16}
---------------------------------

There was no apparent relationship between the experimental context of studies and the control groups that were explored (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). There are, however, clear associations between the study population studied and experimental outcome (Tables [1](#Tab1){ref-type="table"}, [7](#Tab7){ref-type="table"}, [2](#Tab2){ref-type="table"}, [8](#Tab8){ref-type="table"}, [3](#Tab3){ref-type="table"} and [9](#Tab9){ref-type="table"}). For example, within the respiratory burst data, there is a consistent increase in respiratory burst identified by sepsis studies. However, since none of these studies used pre-illness samples, it is unclear if the change is a feature of sepsis, or the study population in relation to healthy volunteers. The conflicting results reported by the three surgical studies are difficult to interpret since each study uses a different burst assay, and the magnitude/type of operation varies. Similar patterns are also evident across the monocyte and lymphocyte studies.

Discussion {#Sec17}
==========

This systematic review has revealed several important issues in the design and reporting of immunologic phenotype in intensive care/sepsis studies. The studies we selected are representative of the current literature, covering the past 15 years of work in three key areas of sepsis research. Following a preliminary Pubmed search, these three assays were chosen because they represent the most frequently investigation for each immune cell type. These limitations refer to the clinical aspects of the study methodology rather than specific laboratory techniques that we did not assess. These data suggest that the use of surgical patients to model critical illness may overcome several key limitations.

Defining what constitutes an adequate control sample for the immunologic study of sepsis is clearly highly challenging. Case--control studies are frequently used in sepsis research. Our review suggests that case-control studies cannot easily determine whether the observed differences in the experimental readout between the study and control groups is due to sepsis per se, or other differences between the groups including age, comorbidities and treatment interventions. Whereas cohort studies do allow pre-sepsis samples to be taken, the majority of studies are conducted in healthy volunteers free of important comorbidities (e.g. heart failure, cirrhosis) that influence both the development of, and survival from, sepsis \[[@CR71]\]. Furthermore, age-, gender- and ethnicity-related differences in immune function are well documented \[[@CR67]--[@CR70]\], yet our data demonstrates that several key demographic details for study and control populations were frequently not reported. Finally, the presence of malignant disease - associated with immunosuppression \[[@CR72]\] and disproportionately represented in the ICU population of most healthcare systems - was only documented in a minority of studies.

Sepsis is currently defined using clinical constructs that define syndromes, rather than use biologic and/or molecular criteria. It remains unclear whether there are biologically relevant differences between clinically defined subtypes of sepsis. In other words, changes in immunophenotype associated with progression of sepsis to severe sepsis/septic shock may merely reflect the consequences of clinical interventions and/or indirect effects on organ function that partly reflect pre-existing comorbidities. Furthermore, the specific detection of pathogens, or pathogen-associated molecular patterns, is likely to further impact on the robustness of immunophenotyping since the location and type of micro-organism both regulate host-immune responses \[[@CR77], [@CR78]\]. We identified only one study that specified infection site and/or a specific pathogen \[[@CR34]\].

Critically ill patients are exposed to a range of therapeutic agents that have well-described immunologic effects. Although immunomodulation by the majority of these agents has been established *in vitro*, their role in confounding the septic immunophenotype remains unclear. Nevertheless, a myriad of off-target, immune effects have been established in pre-clinical *in vivo* models. Many antibiotics target mitochondria and eukaryotic protein synthesis \[[@CR79]\]. Steroids exert potent pro- and anti-inflammatory properties - including inducing lymphocyte apoptosis \[[@CR9]\]. Similarly, sedatives and analgesics exert profound effects on immune cell function \[[@CR80], [@CR81]\].

Our data suggest that surgical patients offer important potential advantages for mechanistic studies of sepsis. The incidence of sepsis - as defined by conventional clinical criteria - varies from 6.98% to 12.25%, depending upon the health care system and database interrogated \[[@CR82]\]. No other patient population allows the collection of highly phenotyped data and individualised control samples prior to a defined traumatic insult. Since the volume of surgery is huge and large scale outcome data can be collected, potential limitations including comorbidities and concomitant therapies can be controlled for.

Conclusions {#Sec18}
===========

We found several important limitations in clinical design associated with translational immunologic studies of human sepsis. Clinical design in mechanistic studies exploring changes in immunophenotype may contribute to the lack of translational therapeutic progress in intensive care medicine. Major elective surgery offers a potential model to overcome many of these methodological limitations.

Take-home message {#Sec19}
-----------------

Systematic review suggests a critical re-evaluation in design of immunologic phenotyping studies conducted in intensive care.

Tweet {#Sec20}
-----

Immunological investigation of septic patients presents methodological challenges that are not considered by many recent studies.

ACCP/SCCM

:   American College of Chest Physicians/Society of Critical Care Medicine

APACHE II

:   Acute Physiology and Chronic Health Evaluation \[[@CR83]\]

APACHE III

:   Acute Physiology and Chronic Health Evaluation \[[@CR84]\]

ASA

:   American Society of Anesthesiologists \[[@CR85]\]

BC

:   Blood culture

CDC NNIS

:   Centre for Disease Control National Nosocomial Infections Surveillance \[[@CR86]\]

ICU

:   Intensive Care Unit

ISS

:   Injury Severity Score \[[@CR87]\]

MODS

:   Multi Organ Dysfunction Score

N/A

:   not applicable

N/S

:   not summarised

SAPS II

:   Simplified Acute Physiology Score

SSC

:   Surviving Sepsis Campaign

SIRS

:   Systemic Inflammatory Response Syndrome.
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